Investigation Launched into Suicide Risk of Ozempic Weight Loss Medication

The European Medicines Agency (EMA) is investigating the popular diabetes and weight loss medications Ozempic and Saxenda, both made by Novo Nordisk, after a small number of users reported an increase in thoughts of suicide and self-harm. These drugs, known as GLP-1 agonists, are used to control blood sugar and aid in weight loss. The investigation will also consider whether other GLP-1 medications should be examined. While the risk is small, it has been known since clinical trials that GLP-1 drugs can increase the risk of suicidal ideation. Experts emphasize the importance of comprehensive management plans and emotional support when using these medications. Novo Nordisk maintains that there is no causal association between their products and suicidal thoughts.